Drug intelligence / Profile preview

NMX-4

Development stage: Preclinical
Lead developer: NovoMedix
Modality: Small Molecules

Overview

NMX-4 is a small molecule drug developed by NovoMedix LLC. It acts as an inhibitor of AMP activated protein kinase (AMPK), ERK subfamily kinases, and interleukin 11 (IL-11). The drug is being investigated for the treatment of skin and musculoskeletal diseases, with a primary focus on skin diseases. Its mechanism involves inhibiting key signaling pathways implicated in inflammation and tissue remodeling. As of the latest update, its highest development status is preclinical[1].

Targets

IL11 (Interleukin-11)ERKAMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on NMX-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMX-4.

Explore the full profile